ROYAL-COMMISSION-ALULA
19.12.2019 22:23:14 CET | Business Wire | Press release
The second Winter at Tantora Festival in AlUla in North West Saudi Arabia starts today – a three-month celebration that will showcase the very best in international music, art and culture connecting East and West as the AlUla county has done for thousands of years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005781/en/
It comes just months after Saudi Arabia introduced tourist visas to citizens from 49 countries making the Kingdom more accessible than ever with the UNESCO World Heritage site at Hegra in AlUla among those featured in a global marketing campaign.
The festival is part of the Cultural Manifesto that was launched by the festival organisers, the Royal Commission for AlUla, in Paris in October as part of a long-term strategy to transform the region and open the region as a global living museum and place of culture, heritage and the arts.
Winter at Tantora will cover 12 weekends from 19th December and host a wide range of events from the world-famous Dakar Rally; international ballooning festival; the world’s second longest endurance horse race; the world’s first desert polo tournament and welcome pop-up restaurants from globally renowned restaurants.
The spectacular mirrored wall Maraya Theatre with its 500-seat capacity and operatic sound quality will be home throughout the festival to some of the world’s leading performers who range from Omar Khairat to Andrea Bocelli.
Festival visitors will also be able to meet and engage with young members of the AlUla community who are benefitting from a diverse range of training programmes in hospitality; culture; nature and the environment and studying overseas including 24 men and women at the FERRANDI Paris culinary institute in Paris.
These young chefs will work alongside Michelin-starred experts during the festival creating world-class cuisine that will incorporate local ingredients from the fertile AlUla valley and blending traditional recipes with modern cuisine.
RCU CEO Amr AlMadani says: “Festival visitors will be given a unique opportunity to visit and experience one of the world’s undiscovered places and its spectacular heritage sites before we reopen them to the world in October 2020.
“They will get a tantalising glimpse of a place that been a cultural crossroads for thousands of years and the chance to see it from the serenity of a hot air balloon; the adrenaline of soaring over the desert and mountains in an open seater biplane or exploring hidden canyons in traditional vintage Land Rovers.”
The Royal Commission for AlUla has also completed major infrastructure work at AlUla airport – increasing capacity fourfold to 400,000 visitors a year and upgrading local mountain resorts to enhance the visitor experience.
AlUla will be a worldwide destination for those seeking a unique experience of the full meaning and context of landscape – an experience that integrates the natural and cultural heritage as one living environment. By safeguarding our precious landscapes and cultural heritage this open-air museum will be the Kingdom’s gift to the world creating remarkable and lasting memories.
‘Authentic AlUla’, the opening weekend, is a celebration rooted in AlUla, to mark the start of the winter planting season at the iconic Tantora sundial from which the festival is named. It is the first of 12 specially themed weekends.
Notes to editors
To find out more about the Winter at Tantora festival and details of packages and the entertainment and cultural programmes, log on to www.experiencealula.com
To find out more about how the Royal Commission for AlUla is working with the community to develop a world-class tourism destination, log on to www.rcu.gov.sa
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005781/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom